Joel Shapiro

Joel Shapiro

Auto-generated profile, based on publicly available information

Joel Shapiro

Erasmus University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
JSJoel Shapiro
Joel Shapiro
JLJ Jan B van Lanschot
J Jan B van Lanschot
MHMaarten C C M Hulshof
Maarten C C M Hulshof
PHPieter van Hagen
Pieter van Hagen
Mark I. van Berge HenegouwenMark I. van Berge Henegouwen
Mark I. van Berge Henegouwen
AGAte van der Gaast
Ate van der Gaast

8 June 2016 in World Journal of Surgery
Verified
Journal Article
Open access
PDF file
BGBrechtje A. Grotenhuis
Brechtje A. Grotenhuis
JSJoël Shapiro
Joël Shapiro
SAStefan van Adrichem
Stefan van Adrichem
MVMarianne de Vries
Marianne de Vries
MKMarcel Koek
Marcel Koek
JLJ. Jan B. van Lanschot
J. Jan B. van Lanschot
Background: Recent studies have suggested that sarcopenia is a prognostic risk indicator of postoperative complications and predicts survival in cancer patients. The aim of this study is to investigate whether sarcopenia is associated with postoperative short‐term outcome (morbidity and mortality) and long‐term survival in patients undergoing esophagectomy for cancer after neoadjuvant chemoradiotherapy.Methods: All patients who underwent neoadjuvant chemoradiotherapy followed by esophagectomy for cancer, and of whom an adequate CT scan was available, were included in the current study. The presence of sarcopenia was defined by CT imaging using cut‐off values of the total cross‐sectional muscle tissue measured transversely at the third lumbar level.Results: A total number of 120 patients were eligible for analysis. Almost half of the patients (N = 54, 45 %) were classified as having sarcopenia; 24 sarcopenic patients (44 %) had overweight and 5 sarcopenic patients (9 %) were obese. Overall morbidity and mortality rate did not differ significantly between sarcopenic and non‐sarcopenic patients, nor did long‐term overall or disease‐free survival. Also sarcopenic obesity was not associated with worse outcome.Conclusion: The presence of sarcopenia was not associated with a negative short‐ and long‐term outcome in this selected group of esophageal cancer patients after neoadjuvant chemoradiotherapy followed by esophagectomy.

1 November 2013 in Annals of Surgery
Verified
Journal Article
Closed access
JSJoel Shapiro
Joel Shapiro
FKFiebo J. W. Ten Kate
Fiebo J. W. Ten Kate
PHPieter van Hagen
Pieter van Hagen
KBKatharina Biermann
Katharina Biermann
BWBas P. L. Wijnhoven
Bas P. L. Wijnhoven
JLJ. Jan B. van Lanschot
J. Jan B. van Lanschot
Objectives: To gain insight into the exact location of residual esophageal cancer in the esophageal wall and regional lymph nodes after neoadjuvant chemoradiotherapy (nCRT) and to determine the pattern of regression. Background: Data from the recently published chemoradiotherapy for oesophageal cancer followed by surgery study trial showed that 49% of squamous cell carcinomas and 23% of adenocarcinomas had a pathologically complete response (pCR) in the resection specimen after nCRT. These results impose the ethical imperative to reconsider the necessity of esophagectomy with its substantial morbidity and mortality in patients with pCR. However, it remains challenging to accurately identify these patients before resection. Methods: Between January 2003 and July 2011, all patients with esophageal cancer in a tertiary referral center, who underwent nCRT (5 weekly courses of carboplatin and paclitaxel plus 41.4 Gy concurrent radiotherapy) and surgical resection, were analyzed. The resection specimens were carefully re-evaluated by an experienced gastrointestinal pathologist. Tumor regression grade (TRG) was meticulously scored for each specific layer of the esophageal wall and for all removed lymph nodes. Results: One hundred two consecutive patients were included. Seventy-one (70%) of 102 patients were noncomplete responders (≥TRG2) and in 63 of these patients (89%), residual tumor cells were seen in the mucosa and/or submucosa. Five of 8 patients without involvement of the mucosa and the submucosa had isolated remnants in the muscle layer (5/102 = 5%); the other 3 patients had tumor cells only in a single lymph node (3/102 = 3%). The surrounding stroma showed the highest percentage of TRG1 ( = pCR: 47%). In patients with pretreatment lymph node positivity, the percentage of TRG1 in all lymph nodes was also favorable (52%). Overall regression showed a nonrandom mixed pattern of both concentric regression and regression toward the lumen. Conclusions: After nCRT for esophageal cancer, both the mucosa and the submucosa show frequent residual malignant involvement. The surrounding stroma and the regional lymph nodes show the highest percentage of pCR and the overall regression pattern is most frequently a mixed pattern of both concentric regression and regression toward the lumen. This overall regression pattern lends support to careful testing of a wait-and-see approach in a subgroup of patients with esophageal cancer after nCRT.

29 June 2015 in JMIR Research Protocols
Verified
Journal Article
Open access
BNBo Jan Noordman
Bo Jan Noordman
JSJoel Shapiro
Joel Shapiro
MSManon C.W. Spaander
Manon C.W. Spaander
KKKausilia K Krishnadath
Kausilia K Krishnadath
HLHanneke Van Laarhoven
Hanneke Van Laarhoven
JLJ Jan B van Lanschot
J Jan B van Lanschot
Results from the recent CROSS trial showed that neoadjuvant chemoradiotherapy (nCRT) significantly increased survival as compared to surgery alone in patients with potentially curable esophageal cancer. Furthermore, in the nCRT arm 49% of patients with a squamous cell carcinoma (SCC) and 23% of patients with an adenocarcinoma (AC) had a pathologically complete response in the resection specimen. These results provide a rationale to reconsider and study the timing and necessity of esophagectomy in (all) patients after application of the CROSS regimen. We propose a "surgery as needed" approach after completion of nCRT. In this approach, patients will undergo active surveillance after completion of nCRT. Surgical resection would be offered only to those patients in whom residual disease or a locoregional recurrence is highly suspected or proven. However, before a surgery as needed approach in oesophageal cancer patients (SANO) can be tested in a randomized controlled trial, we aim to determine the accuracy of detecting the presence or absence of residual disease after nCRT (preSANO trial). This study is set up as a prospective, single arm, multicenter, diagnostic trial. Operable patients with potentially curable SCC or AC of the esophagus or esophagogastric junction will be included. Approximately 4-6 weeks after completion of nCRT all included patients will undergo a first clinical response evaluation (CRE-I) including endoscopy with (random) conventional mucosal biopsies of the primary tumor site and of any other suspected lesions in the esophagus and radial endo-ultrasonography (EUS) for measurement of tumor thickness and area. Patients in whom no locoregional or disseminated disease can be proven by cytohistology will be offered a postponed surgical resection 6-8 weeks after CRE-I (ie, approximately 12-14 weeks after completion of nCRT). In the week preceding the postponed surgical resection, a second clinical response evaluation (CRE-II) will be planned that will include a whole body PET-CT, followed again by endoscopy with (random) conventional mucosal biopsies of the primary tumor site and any other suspected lesions in the esophagus, radial EUS for measurement of tumor thickness and area, and linear EUS plus fine needle aspiration of PET-positive lesions and/or suspected lymph nodes. The main study parameter is the correlation between the clinical response assessment during CRE-I and CRE-II and the final pathological response in the resection specimen. The first patient was enrolled on July 23, 2013, and results are expected in January 2016. If this preSANO trial shows that the presence or absence of residual tumor can be predicted reliably 6 or 12 weeks after completion of nCRT, a randomized trial comparing nCRT plus standard surgery versus chemoradiotherapy plus "surgery as needed" will be conducted (SANO trial). Netherlands Trial Register: NTR4834; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4834 (archived by Webcite at http://www.webcitation.org/6Ze7mn67B).

1 October 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MFMatthieu Faron
Matthieu Faron
MCMaurice Cheugoua-Zanetsie
Maurice Cheugoua-Zanetsie
JTJayne Tierney
Jayne Tierney
PTPierre Thirion
Pierre Thirion
MNMatthew Nankivell
Matthew Nankivell
JWJohn Wong
John Wong
PURPOSE: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups. PATIENTS AND METHODS: All, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158). RESULTS: IPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99), P = .03 and HR = 0.77 (0.68 to 0.87), P < .001 respectively. The NMA comparison of CRS versus CS for OS gave a HR of 0.90 (0.74 to 1.09), P = .27 (consistency P = .26, heterogeneity P = .0038). For CS versus S, a larger effect on OS was observed for GEJ versus TE tumors ( P = .036). For the CRS versus S and CRS versus CS, a larger effect on OS was observed for women ( P = .003, .012, respectively). CONCLUSION: Neoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified.

26 April 2016 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
JSJ. Shapiro
J. Shapiro
DKD. van Klaveren
D. van Klaveren
SLS. M. Lagarde
S. M. Lagarde
ETE L A Toxopeus
E L A Toxopeus
AGA. van der Gaast
A. van der Gaast
JLJ. J. B. van Lanschot
J. J. B. van Lanschot